Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium Lu 177 FF58
- Development stage
- Phase 1
- Lead developer
- Advanced Accelerator Applications
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lutetium Lu 177 FF58 is a radioconjugate composed of the small molecule FF58, which targets the transmembrane receptors integrin alpha V beta 3 (αvβ3) and alpha V beta 5 (αvβ5), linked to the beta-emitting radioisotope lutetium-177. It is designed as a radioligand therapy for cancer treatment. The mechanism involves selective binding to integrin αvβ3/5 on tumor cells, delivering targeted ionizing radiation that can damage or kill cancer cells. The drug was developed by Advanced Accelerator Applications (a Novartis subsidiary) and Novartis for use in advanced solid tumors including pancreatic ductal adenocarcinoma, gastroesophageal junction adenocarcinoma, and glioblastoma multiforme. Clinical development reached Phase I before being terminated; no safety concerns were cited for termination[1][4][5][7].
- Other names
- lutetium Lu 177 FF58177 lutetium labelled FF58
02
Targets
αVβ5 (Integrin αVβ5)αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on lutetium Lu 177 FF58.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium Lu 177 FF58.